All the Therapeutic System Drugs
TNF Blocking Agent. Adalimumab 50 mg/ml.. PRE-FILLED SYRINGE: 2 ×(20 mg/0.4 mL, 40mg/0.8ml)
PRE-FILLED PEN: 2× (40mg /0.8 ml).
Dosage ajust. individ. accord. to pt. med. condit.
RA: in comb. with methotrexate-tmt. of moder.-sev., active RA in adult pts. when the response to dis.-modif. anti-rheumat.drugs includ. methotrexate has been inadequate.
The tmt. of sev., active and progres. RA in adult.not previous. treated with methotrexate, given as monother. in case of intolerance to methotrexate or when continued tmt. with methotrexate is inappropr. AMGEVITA has been shown to reduce the rate of progress. of joint damage as measured by X-ray and to improve physical funct., when given in comb. with methotrexate.
Axial spondyloarthritis Ankylosing spond. (AS): tmt. of adult. with severe active AS who have had an inadeq. response to convent. ther.
Axial spondyloarthritis without radiograph. evidence of AS: tmt. of adults with sev. axial spondyloarthritis without radiograph.evidence of AS, but with object. signs of inflamm. by radiolog. and/or lab. tests includ. MRI and serum CRP levels, who have had an inadequate response to, or are intoler, to,NSAID’s.
Psoriatic arthritis: tmt. of active and progress. psoriat. arthritis in adults when the response to previous dis.-modif. anti-rheum.drug ther. has been inadequate. Adalimumab has been shown to reduce the rate of progress. of peripher. joint damage as measured by X-ray in pts. with polyarticular symmetr. subtypes of the dis. and to improve physic. func.
Psoriasis: tmt. of moder.-sev. chron. plaque psoriasis in adult pts. who are candidates for system. ther.
Hidradenitis suppurativa (HS): tmt. of active moder.- sev. hidradenitis suppurativa (acne inversa) in adult pts. with an inadequate response to convent. system. HS ther.
Crohn’s dis. : reducing signs and sympt.and induc.and maintain. clinical remiss. in adult pts. with moder.- sev. active Crohn’s dis. who have had an inadequate response to convent. ther. AMGEVITA is indic. for reduc. signs and sympt. and induc. clinical remiss. in these pts. if they have also lost response to or are intoler. to infliximab.
Ulcerat. colit.: tmt. of moder.-sev. active ulcerat. colit. in adult pts. who have had an inadequate response to convent. ther. includ. corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intoler. to or have med. contraindicat. for such therapies.
Uveitis : tmt. of non-infect. intermed., posterior and panuveitis in adult pts. who have had an inadequate response to corticosteroids, in pts. in need of corticosteroid-sparing, or in whom corticosteroid tmt. is inappropr.
Intestinal Behcet's dis.: tmt. of intestin. Behcet’s dis. in pts. who have had an inadequate response to convention. ther.
C/I: Hypersens.
Active tuberculosis or other sev. infect. such as sepsis, and opportunist.infec.
Moder.-sev. HF(NYHA class III/IV).
Tetrahydrazoline (HCl) 0.05%. EYE DROPS: 15 cc. 1-2 drops 3 x dly.
Allerg. and vernal conjunct., irrit. due to
smoke, smog, wind, dust, sun, eye fatigue
due to driving, reading.
Antiseptic. Boric Acid 1.9%. EYE DROPS: 10 ml. Wash eye as needed.
Cleaning eyes, wash. foreign bodies.
NSAID. Bromfenac (as sodium sesquihydrate) 0.075% w/w. ophtalmic sol. 5ml. One drop appl. to the affect. eye twice daily (morn. and even.) 1 day prior to surg., the day of surg., and 14 days post-surg. To be admin. at least 5 min. after other topic. medic.
tmt. of postoper. inflam. and prevent. of ocular pain in adlt pts. undergoing cataract surg.
C/I:Hypersens.
Mast Cell Stabilizer. Sodium Cromoglycate 20 mg/ml. EYE DROPS (preserv. free): 10 ml. 1 drop
in ea. eye 4 x dly. Max. dly dose: 8
drops in ea. eye.
Prevent. tmt. all types allerg. conjunctivit.
C/I: Hypersens., not to be used with
contact lenses and at least 15 mins. aft.
tmt.
Mast Cell Stabilizer. Sodium Cromoglycate 2%. EYE DROPS: 13.5 ml. Adults and child
over 12 yrs: 1-2 drops in ea. eye 4-6 x
dly. Child under 12 yrs: 1-2 drops in ea.
eye 2-6 x dly.
Allerg. conjunct.
